Advertisement

Rutgers Cancer Institute Welcomes New Oncology Leadership


Advertisement
Get Permission

RUTGERS CANCER INSTITUTE of New Jersey at the University Hospital in Newark has named several new oncology leaders, further enhancing the facility’s expertise and ability to deliver National Cancer Institute (NCI)-designated comprehensive cancer center services to the greater Essex County region.

Wadih Arap, MD, PhD

Wadih Arap, MD, PhD

Serving as the new Director for Rutgers Cancer Institute of New Jersey at University Hospital is Wadih Arap, MD, PhD. Dr. Arap previously served as Chief of the Hematology/Oncology Division and Deputy Director at the University of New Mexico Comprehensive Cancer Center. Dr. Arap also will serve as Chief in the Division of Hematology/Oncology in the Department of Medicine at Rutgers New Jersey Medical School. Dr. Arap aims to build on the partnership goals of enhancing clinical trial access to patients in the region as well as expanding community outreach, education, and screening programs.

Renata Pasqualini, PhD

Renata Pasqualini, PhD

To add to the leadership on the Newark campus, Renata Pasqualini, PhD, has been named as Chief of the Division of Cancer Biology in the Department of Radiation Oncology at Rutgers New Jersey Medical School. Prior to her new role, Dr. Pasqualini served as Associate Director for Translational Research and Chief of the Division of Molecular Medicine at the University of New Mexico Comprehensive Cancer Center. Drs. Pasqualini and Arap have led a joint laboratory program for 20 years and are in fact a husband-and-wife team.

Each has previously held leadership positions during their 14-year tenure at The University of Texas MD Anderson Cancer Center. Together, they have made groundbreaking discoveries about the diversity of blood vessels in normal and diseased organs. The couple advanced their studies of the vascular and lymphatic systems from laboratory models into human patients and used what they had learned to develop potential targeted therapies. Together, the pair hopes to bring important advances to science and medicine, as they actively integrate research and drug-development efforts at the Rutgers Cancer Institute of New Jersey at University Hospital in Newark. ■


Advertisement

Advertisement



;
Advertisement